• Organizations: Tenpoint Therapeutics
FDA accepts Tenpoint's Brimochol PF NDA for presbyopia
Pipeline

FDA accepts Tenpoint's Brimochol PF NDA for presbyopia

Fixed-dose-combo eye drop of brimonidine tartrate and carbachol has demonstrated a statistically significant reduction in pupil size up to 10 hours; PDUFA date set for January.
Tenpoint submits NDA for Brimochol PF for presbyopia
Pipeline

Tenpoint submits NDA for Brimochol PF for presbyopia

The FDA begins a 60-day review period to determine if the submission for the pupil-modulating eye drop is acceptable.
Tenpoint Therapeutics names veteran executive as first CCO
Business

Tenpoint Therapeutics names veteran executive as first CCO

Carol Kearney to lead company’s efforts to launch and expand global availability of BRIMOCHOL PF for presbyopia.
Tenpoint reports positive topline data from phase 3 presbyopia eye drop study
Pipeline

Tenpoint reports positive topline data from phase 3 presbyopia eye drop study

With BRIMOCHOL PF meeting its prespecified primary endpoints, the company is planning for a regulatory filing within the first half of 2025.
Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements
Business

Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements

Newly-combined Tenpoint Therapeutics, Ltd includes a pipeline featuring BRIMOCHOL PF, a once-daily eye drop for presbyopia targeting an NDA filing in 2025.
Tenpoint Therapeutics launches with focus on regenerative medicine for degenerative ocular diseases
Research

Tenpoint Therapeutics launches with focus on regenerative medicine for degenerative ocular diseases

Company secured $70 million in Series A financing for advancing engineered, cell-based therapies.